Contents

1. Case Definitions in Drug-resistant Tuberculosis **1**
- Treatment Outcomes in DOTS-PLUS *2*

2. Antitubercular Drugs Used in Previously Treated Patients of Tuberculosis and their Adverse Effects **4**
- Kanamycin *4*
- Amikacin *12*
- Capreomycin *14*
- Ethionamide and Prothionamide *16*
- Cycloserine *18*
- Para-aminosalicylic Acid (PAS) *20*
- Levofloxacin *22*
- Moxifloxacin *24*
- Ofloxacin *26*
- Clofazimine *27*
- Thiacetazone *29*
- Clarithromycin *30*
- Linezolid *31*
- Imipenem/Cilastatin *31*
- Amoxicillin Clavulanate *32*

3. Management of Retreatment Cases in Tuberculosis **35**
- Relapse *35*
- Defaulters or Treatment after Default *36*
- Failure *36*
- Poor Adherence to Treatment *37*
- Drug Resistant Tuberculosis *37*
- Prevention of Retreatment Cases *43*

4. Mono- and Poly-drug-resistant Tuberculosis: Current Status **47**
- Definition *47*
- Types of Drug Resistance *47*
- Prevalence of Mono- and Poly-drug Resistance: Global Scenario *48*
- Prevalence of Mono- and Poly-drug Resistance: India *50*
- Mechanism of Drug Resistance *52*
- HIV Infection and Drug-resistant Tuberculosis *52*
- Risk Factors of Mono- and Poly-drug Resistance *53*
- Sources and Causes of Mono- and Poly-drug Resistance *54*

5. Mono- and Poly-drug-resistant Tuberculosis: Treatment 57
- Impact of Mono- and Poly-drug Resistance on the Outcome of Chemotherapy *57*
- General Principles for Designing Treatment Regimen for Mono- and Poly-drug-resistant TB *58*
- Development of Further Resistance *60*

6. Multi-drug-resistant Tuberculosis: Current Status 61
- Definition *61*
- Types of Drug Resistance *61*
- Prevalence of MDR-TB: Global Scenario *62*
- Trends in MDR-TB: Global Scenario *65*
- Prevalence of MDR-TB: India *66*
- HIV Infection and Multi-drug-resistant Tuberculosis *69*
- Risk Factors of MDR-TB *71*
- Sources and Causes of MDR-TB *71*
- Control of MDR-TB *72*

7. Multi-drug-resistant Tuberculosis: Case Finding Strategies 77
- Targeting Risk Groups for Drug Susceptibility Test (DST) *77*
- Strategies for Programs with Minimal Access to DST and Limited Resources *78*

8. Multi-drug-resistant Tuberculosis: Laboratory Issues 82
- General Considerations *82*
- Essential Laboratory Services and Infrastructure *83*
- Organization of the Laboratory Network *83*
- Drug Susceptibility Testing (DST) *85*
- Limitations of DST *87*
- Rational Use of DST in DR-TB Control Programs *87*
- Time for Testing and Reporting: Turnaround Time *88*
- Infection Control and Biosafety in the Laboratory *88*
- Quality Control and Quality Assurance *89*

9. Multi-drug-resistant Tuberculosis: Diagnosis and Treatment 92
- Definition *92*
- Mechanism of Drug Resistance *92*
- Genetic Basis of Drug Resistance *93*
- Virulence and Drug-resistant Strains *93*
- Impact of Drug Resistance on the Outcome of Chemotherapy *93*
- Diagnosis of Multi-drug-resistant Tuberculosis *94*
- Treatment of Multi-drug-resistant Tuberculosis *98*
- Immunotherapy or Immunomodulation *105*
- Outcome of Treatment *106*

10. Multi-drug-resistant Tuberculosis: Management in Special Situations 112
- M/XDR-TB in Pregnancy *112*
- M/XDR-TB in Breastfeeding *113*
- M/XDR-TB in Contraception *114*
- M/XDR-TB in Children *114*
- M/XDR-TB in Diabetes Mellitus *115*
- M/XDR-TB in Renal Insufficiency *116*
- M/XDR-TB in Liver Disorders *117*
- M/XDR-TB in Seizure Disorders *117*
- M/XDR-TB in Substance Dependence *118*
- M/XDR-TB in Patients with Psychosis *118*

11. Multi-drug-resistant Tuberculosis: Monitoring of Treatment and Adverse Drug Reaction 120
- Pretreatment Screening and Evaluation *120*
- Monitoring Progress of Treatment *121*
- Monitoring for Adverse Effects During Treatment *122*
- Management of Adverse Effects *123*

12. Multi-drug-resistant Tuberculosis: Case-based Approach 128

13. Multi-drug-resistant Tuberculosis: Adherence to Therapy 138
- Education of Patients and their Families *138*
- Treatment Delivery Settings *138*
- Adherence to Therapy *139*
- Directly Observed Therapy (DOT) *139*
- Who can Deliver DOT for MDR-TB Patients? *139*
- Alternative to DOT for MDR-TB Patients *140*
- Maintaining Confidentiality *140*
- Socioeconomic Interventions *140*
- Social and Emotional Support *140*
- Follow-up of the Nonadherent Patient *141*
- Early and Effective Management of Adverse Drug Effects *141*

14. Multi-drug-resistant Tuberculosis Contacts: Management 143
- Management of Symptomatic Adult Contacts of Patients with MDR-TB *143*
- Management of Symptomatic Pediatric Contacts of Patients with MDR-TB *144*
- Chemoprophylaxis of Contacts of DR-TB Index Cases *145*

15. Extensively Drug-resistant Tuberculosis: Current Status 147
- Definition *147*
- Prevalence of XDR-TB: Global Scenario *148*
- Mechanisms of Resistance in XDR-TB *149*
- Resistance Determinants *151*
- Factors Responsible for XDR-TB *152*
- XDR-TB and HIV *152*

16. Extensively Drug-resistant Tuberculosis: Diagnosis 157
- Conventional Phenotypic Methods for the Diagnosis in Solid Media *157*
- Phenotypic Methods for the Diagnosis in Liquid Media *159*
- New Phenotypic Methods *159*
- Genotypic Methods *162*
- Genotype MTBDRplus *163*

17. Extensively Drug-resistant Tuberculosis: Management 168
- Management Guidelines for Patients with Documented, or Almost Certain, XDR-TB *168*
- Monitoring of Treatment *170*
- Role of Surgery *171*
- Human Immunodeficiency Virus (HIV) and XDR-TB *171*
- XDR-TB in Pediatric Patients *171*
- XDR-TB in Pregnancy *173*
- WHO Response Strategies for XDR-TB? *174*
- Management of Contacts of XDR-TB Patients *174*
- Treatment Outcome in XDR-TB *175*
- Control of XDR-TB *176*

18. Extensively Drug-resistant Tuberculosis Failure: Management 179
- Assessment of Patients at Risk for Treatment Failure *179*
- Indications for Suspending Treatment *180*
- Suspending Therapy *180*
- Approach to Suspending Therapy *181*
- Supportive Care for Patients in whom all the Possibilities of XDR-TB Treatment have Failed *181*

19. Drug Resistance in Extrapulmonary Tuberculosis 183
- Epidemiology *183*
- Diagnosis of Drug Resistance in Extrapulmonary Tuberculosis *185*
- Management of Drug Resistance in Extrapulmonary Tuberculosis *185*
- Monitoring of Drug Resistance in Extrapulmonary Tuberculosis *185*
- Role of Surgery in Drug-resistant Extrapulmonary Tuberculosis *185*
- Treatment Success in Drug-resistant Extrapulmonary Cases *186*
- Problems in Management of Drug Resistance in Extrapulmonary Tuberculosis *186*
- Drug-resistant Central Nervous System Tuberculosis *187*
- Tuberculosis Drugs and their CNS Penetration *187*

20. Fluoroquinolone Resistance in Tuberculosis 189
- Prevalence of Fluoroquinolone Resistance *189*
- Mechanism of Resistance to Fluoroquinolones *190*
- Cross Resistance amongst Fluoroquinolones *190*
- Minimum Inhibitory Concentration of Fluoroquinolones *191*
- Early Bactericidal Activity *191*
- Development of Resistance During Treatment *192*
- Treatment Outcome in Fluoroquinolone-resistant Tuberculosis Patients *193*

21. Multi-drug-resistant and Extensively Drug-resistant Tuberculosis and HIV 197
- Relationship HIV and M/XDR-TB *197*
- Collaborative TB/HIV Activities *199*
- Clinical Features and Diagnosis of M/XDR-TB in HIV-infected Patients *200*
- Concomitant Treatment of M/XDR-TB and HIV *201*
- XDR-TB and HIV *207*
- Implications of HIV for M/XDR-TB Infection Control *207*

22. Interaction between Antitubercular and Antiretroviral Drugs 211
- Antiretroviral Therapy for the Treatment of HIV Infection *211*
- Pharmacokinetic Issues in the Treatment of HIV-related Tuberculosis *214*
- Interaction between Antiretroviral and Antitubercular Drugs *214*
- Drug-drug Interactions in the Treatment of HIV and Drug Resistant-TB (DR-TB) *216*

23. Multi-drug-resistant and Extensively Drug-resistant Tuberculosis: Prevention 218
- General Guidelines for the Prevention of MDR and XDR-TB *219*

24. Drug-resistant Tuberculosis in Children 225
- Epidemiology *225*
- Pathogenesis *226*
- Diagnosis of DR-TB in Children *227*
- Treatment of DR-TB in Children *227*
- Other Adjunctive Treatments *230*
- Treatment Duration for MDR-TB in Children *231*
- XDR-TB in Children *231*
- Management of Comorbid Conditions *233*
- Treatment Monitoring *233*

25. Tuberculosis Control in India: DOTS-Plus 236
- Framework *236*
- Case Finding Strategy *237*
- Enrolment into DOTS-Plus Program *238*

- Confirmed MDR-TB Case *238*
- Drug-resistant TB Center *239*
- Pretreatment Evaluation *240*
- Counseling *241*
- Monitoring Progress During Treatment *241*
- Category IV Regimen *242*
- Drug Dosages and Administration *243*
- Treatment Duration *244*
- Regimen for XDR-TB *244*
- Duration of Regimen for XDR-TB *244*
- Treatment Interruption and Default *245*
- Treatment Outcomes *246*
- Providing Patient and Family Counseling *246*
- Monitoring for Early Detection of Adverse Reactions *247*
- Role of DR-TB Committee in the Management of Adverse Reactions *248*
- Adherence *248*
- Follow-up of the Nonadherent Patient *248*
- DOTS-Plus Plan *249*

26. Infection Control in Multi-drug-resistant Tuberculosis 251
- Administrative Controls *251*
- Environmental Controls *252*
- Personal Respiratory Protection (Special Masks) *253*
- Role of Rapid Tests in Infection Control *254*

27. Newer Antitubercular Drugs 255
- Difficulties in Antitubercular Drug Development *255*
- Priorities in Developing Antitubercular Drugs *256*
- Methods to Develop Newer Antitubercular Drugs *256*
- Emerging Pipeline of New Anti-TB Drugs *256*
- Adjunctive Immunotherapy in MDR-TB and XDR-TB *262*

Index *269*